{"name": "Cipla",
 "permalink": "cipla",
 "crunchbase_url": "http://www.crunchbase.com/company/cipla",
 "homepage_url": "http://www.cipla.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "91 22 2308 2891",
 "description": "",
 "created_at": "Fri Jun 18 01:08:29 UTC 2010",
 "updated_at": "Fri Jun 18 01:09:15 UTC 2010",
 "overview": "\u003Cp\u003ECipla, is a prominent Indian pharmaceutical company, best-known outside its home country for manufacturing low-cost anti-AIDS  drugs for HIV-positive patients in developing countries. Founded by Khwaja Abdul Hamied as The Chemical, Industrial \u0026amp; Pharmaceutical Laboratories, Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in more than 180 countries worldwide. Among the hundreds of generic medications it produces for international distribution are atorvastatin, amlodipine, fluoxetine, venlafaxine hydrochloride and metformin. Recently, Cipla sold the manufacturing rights of its high-end emergency contraceptive pill, I-pill, to its pharma field counterpart Nicholas Piramal (Piramal Healthcare) for Rs. 95 million. Cipla earned a revenue of total Rs. 33 million (approx.) from the sales of their popular contraceptive pill, to date.\u003C/p\u003E",
 "image": null,
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Mumbai Central",
    "address2": "",
    "zip_code": "400 008",
    "city": "Mumbai, Maharashtra",
    "state_code": null,
    "country_code": "IND",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Cipla targets $19B biosimilar market with string of new deals\r\n",
    "stoned_year": 2010,
    "stoned_month": 6,
    "stoned_day": 16,
    "source_url": "http://www.fiercebiotech.com/story/cipla-targets-19b-biosimilar-market-string-new-deals/2010-06-16?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Cipla targets $19B biosimilar market with string of new deals",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Cipla",
      "permalink": "cipla"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}